Home » Stocks » SIEN

Sientra, Inc. (SIEN)

Stock Price: $4.72 USD 0.10 (2.06%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $4.56 -0.16 (-3.29%) Jan 22, 4:58 PM
Market Cap 237.89M
Revenue (ttm) 71.81M
Net Income (ttm) -88.96M
Shares Out 50.39M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.72
Previous Close $4.62
Change ($) 0.10
Change (%) 2.06%
Day's Open 4.57
Day's Range 4.50 - 4.79
Day's Volume 589,506
52-Week Range 1.00 - 6.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 months ago

Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Sientra (SIEN) delivered earnings and revenue surprises of 13.16% and 38.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Reports record Breast Products net sales of $15.3 million, representing 54% sequential growth and 2 1 % year over year growth

GlobeNewsWire - 2 months ago

Jeffrey Nugent, Current Chairman and Chief Executive Officer, Announces His Retirement

GlobeNewsWire - 2 months ago

SANTA BARBARA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that members of ma...

Zacks Investment Research - 2 months ago

Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

SANTA BARBARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that it will relea...

GlobeNewsWire - 4 months ago

Marks First Regulatory approval of Sientra Breast Implants Outside of the U.S. Marks First Regulatory approval of Sientra Breast Implants Outside of the U.S.

24/7 Wall Street - 5 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: APTX, CBAY, EOLS, IBIO
Seeking Alpha - 5 months ago

Sientra, Inc. (SIEN) CEO Jeffrey Nugent on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Sientra (SIEN) delivered earnings and revenue surprises of 15.56% and 40.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Continued Strength in Core Breast Products Business Despite COVID-19 Headwinds

GlobeNewsWire - 5 months ago

SANTA BARBARA, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today the company will be participating in the upcoming virtual...

GlobeNewsWire - 5 months ago

SANTA BARBARA, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that it will rel...

GlobeNewsWire - 6 months ago

SANTA BARBARA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today that Jeff Nugent, President and Chief Executive Officer, ...

Seeking Alpha - 8 months ago

Sientra, Inc. (SIEN) CEO Jeffrey Nugent on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Sientra (SIEN) delivered earnings and revenue surprises of 10.20% and -9.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Investors need to pay close attention to Sientra (SIEN) stock based on the movements in the options market lately.

Seeking Alpha - 10 months ago

Sientra, Inc. (SIEN) CEO Jeff Nugent on Q4 2019 - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Sientra (SIEN) delivered earnings and revenue surprises of 7.14% and 0.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 11 months ago

SANTA BARBARA, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that on February 13, 2020, t...

GlobeNewsWire - 1 year ago

SANTA BARBARA, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, today announced that on December 3, 2019, the Compensation Committee of t...

The Motley Fool - 1 year ago

Aesthetics surgery is a big market, and these three companies are positioned to win from its growth.

Other stocks mentioned: CUTR, INMD
The Motley Fool - 1 year ago

What should investors think of Sientra after its impressive Q3 results?

Seeking Alpha - 1 year ago

Sientra's (SIEN) CEO Jeff Nugent on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Shares pop after the company reports impressive third-quarter results.

GlobeNewsWire - 1 year ago

SANTA BARBARA, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (Nasdaq: SIEN), a medical aesthetics company, announced today that its management team will participate in the followin...

Zacks Investment Research - 1 year ago

As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

Other stocks mentioned: AGN, JNJ
Zacks Investment Research - 1 year ago

As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

Other stocks mentioned: AGN, JNJ
GlobeNewsWire - 1 year ago

SANTA BARBARA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, today announced that on September 12, 2019, the Compensation Committee o...

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CPE, GLMD, TELL, VKTX
24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ECA, EVH, FLMN, VSLR
Seeking Alpha - 1 year ago

Sientra's (SIEN) CEO Jeff Nugent on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AGRX, CTST, HIMX, NOG
Benzinga - 1 year ago

Shares of Sientra Inc (NASDAQ: SIEN) have declined about 25 percent since the company reported its first-quarter results on May 8.

Seeking Alpha - 1 year ago

Sientra, Inc. (SIEN) CEO Jeff Nugent on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Sientra (SIEN) delivered earnings and revenue surprises of -19.74% and 3.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 year ago

The FDA approved a design change for the company's Opus breast implants.

The Motley Fool - 1 year ago

Investors are worried about the aesthetics company's profitability.

About SIEN

Sientra, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers;... [Read more...]

Industry
Medical Devices
IPO Date
Oct 29, 2014
CEO
Jeffrey Nugent
Employees
339
Stock Exchange
NASDAQ
Ticker Symbol
SIEN
Full Company Profile

Financial Performance

In 2019, Sientra's revenue was $83.70 million, an increase of 22.86% compared to the previous year's $68.13 million. Losses were -$106.82 million, 29.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Sientra stock is "Strong Buy." The 12-month stock price forecast is 7.57, which is an increase of 60.55% from the latest price.

Price Target
$7.57
(60.55% upside)
Analyst Consensus: Strong Buy